Form 4: Clene Inc. Director Receives Stock Option Grant

Director Vallerie McLaughlin was granted stock options for 3,564 shares of Clene Inc. common stock on May 21, 2026.

Summary

• Director Vallerie McLaughlin received two separate grants of stock options totaling 3,564 shares.
• The options have an exercise price of $6.81 per share.
• 1,500 options vest in 12 equal monthly installments starting June 21, 2026.
• 2,064 options vested immediately upon the grant date of May 21, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Issuance of stock options results in potential future dilution for existing shareholders.

Risks

• Market price volatility may affect the value of the granted options.
• The exercise price of $6.81 may be higher than future market prices, rendering options underwater.

Future Outlook

The options expire on May 20, 2036, reflecting a long-term incentive structure for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to align leadership incentives with long-term shareholder value in the biotechnology sector.

Comparison to Industry Standards

• The use of the 2020 Stock Plan for director compensation is consistent with standard practices for small-cap biotech firms.
• Vesting schedules involving a mix of immediate and monthly installments are common for board members.

Corporate Governance

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new options.

Next Steps

• Vesting of the 1,500 share grant in monthly installments beginning June 21, 2026.

Key Dates

Keywords

Clene Inc, CLNN, Form 4, Insider Trading, Stock Options, Director Compensation